Concepedia

M de Boer-Dennert

MD

24

Publications

1.7K

Citations

19

H-Index

1993

Active since

Affiliations

Rotterdam University of Applied Sciences(Current)

Erasmus MC Cancer Institute

Slotervaartziekenhuis

The Netherlands Cancer Institute

Utrecht University

M de Boer-Dennert is an author at Rotterdam University of Applied Sciences specializing in medicine, pharmacology, and radiation oncology.

Top concepts

Publications per year

1993–2004

24

Publications

24

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists

M de Boer-Dennert, Ronald de Wit, PIM Schmitz et al. · British Journal of Cancer · 1997 · 375 citations · Full text

, , +8

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

JHM Schellens, Jun Ma, A.S.T. Planting et al. · British Journal of Cancer · 1996 · 146 citations · Full text

, , +9

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor

JHM Schellens, G.J. Creemers, Hilde Rosing et al. · British Journal of Cancer · 1996 · 130 citations · Full text

, , +5

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

Jaap Verweij, Birthe Lund, Jos H. Beijnen et al. · Annals of Oncology · 1993 · 123 citations · Full text

, , +7

Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.

Johanneke E.A. Portielje, Wim H.J. Kruit, Martin Schüler et al. · PubMed · 1999 · 119 citations

, , +15

Rows per page

1–5 of 24